EUVIMEDEUVIMED entdecken
Randomisierte kontrollierte Studie

Dasiglucagon Treatment for Postprandial Hypoglycemia After Gastric Bypass: A Randomized, Double-Blind, Placebo-Controlled Trial

Casper K Nielsen, Caroline C Øhrstrøm, Inas J K Houji, Mads M Helsted, Liva S L Krogh, Nicklas J Johansen, Bolette Hartmann, Jens J Holst iD, Tina Vilsbøll, Filip K Knop iD

Diabetes Care · 01.12.2023 · 46 (12) · 2208-2217

DOI: 10.2337/dc23-1193 ↗

Kurz gefasst

Randomisierte kontrollierte Studie in der Zeitschrift Diabetes Care, online erschienen am 11.10.2023. Verfasst von Casper K Nielsen und 9 weiteren Autor:innen. Beteiligte Einrichtung: Center for Clinical Metabolic Research, Copenhagen University Hospital-Herlev and Gentofte, Hellerup, Denmark. Hauptthemen laut MEDLINE: Gastric Bypass, Hypoglycemia. Die Arbeit wurde bisher 16-mal zitiert (Crossref) und nennt 35 Literaturangaben. Gefördert von: Zealand Pharma A/S.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

OBJECTIVE Postbariatric hypoglycemia affects >50% of individuals who have undergone Roux-en-Y gastric bypass surgery. Despite the often debilitating nature of this complication, existing treatment options are limited and often inefficient. Dasiglucagon is a stable glucagon analog available in a ready-to-use formulation and was recently shown to mitigate postbariatric hypoglycemia in experimental settings. Here, we aimed to evaluate the hypoglycemic hindering potential of dasiglucagon in an outpatient trial. RESEARCH DESIGN AND METHODS We conducted a randomized, double-blind, placebo-controlled, crossover, proof-of-concept study at the Center for Clinical Metabolic Research at Gentofte Hospital in Denmark. The study included 24 individuals who had undergone Roux-en-Y gastric bypass surgery (n = 23 women) with continuous glucose monitor–verified postbariatric hypoglycemia (≥15 min at <3.9 mmol/L three or more times per week) randomly assigned to two treatment periods of 4 weeks of self-administered subcutaneous dasiglucagon at 120 μg or placebo. The primary and key secondary outcomes were continuous glucose monitor–captured percentage of time in level 1 and 2 hypoglycemia (<3.9 and <3.0 mmol/L), respectively. RESULTS Compared with placebo, treatment with dasiglucagon significantly reduced time in level 1 hypoglycemia by 33% (−1.2 percentage points; 95% CI −2.0 to −0.5; P = 0.002) and time in level 2 hypoglycemia by 54% (−0.4 percentage points; 95% CI −0.6 to −0.2; P < 0.0001). Furthermore, dasiglucagon corrected hypoglycemia within 15 min in 401 of 412 self-administrations, compared with 104 of 357 placebo self-administrations (97.3% vs. 29.1% correction of hypoglycemia rate; P < 0.001). Dasiglucagon was generally well tolerated, with mostly mild to moderate adverse events of nausea. CONCLUSIONS Compared with placebo, 4 weeks of self-administered dasiglucagon effectively reduced clinically relevant hypoglycemia in individuals who had undergone Roux-en-Y gastric bypass surgery.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

Gastric BypassHypoglycemiaHumansFemaleGlucagonBlood GlucoseDouble-Blind Method

Substanzen

dasiglucagonGlucagonBlood Glucose

Autor:innen und Institutionen

  • Center for Clinical Metabolic Research, Copenhagen University Hospital-Herlev and Gentofte, Hellerup, Denmark.
  • Department of Clinical Medicine, Faculty of Health and Medical Sciences, University of Copenhagen, Copenhagen, Denmark.
  • Department of Medicine, Zealand University Hospital, Køge, Denmark.
  • Department of Biomedical Sciences, Faculty of Health and Medical Sciences, University of Copenhagen, Copenhagen, Denmark.
  • Novo Nordisk Foundation Center for Basic Metabolic Research, Faculty of Health and Medical Sciences, University of Copenhagen, Copenhagen, Denmark.
  • Clinical Research, Steno Diabetes Center Copenhagen, Herlev, Denmark.

ORCID-Profile: Jens J Holst, Filip K Knop

Förderung

  • Zealand Pharma A/S

Zitieren

APA

Nielsen, C. K., Øhrstrøm, C. C., Houji, I. J. K., Helsted, M. M., Krogh, L. S. L., Johansen, N. J., Hartmann, B., Holst, J. J., Vilsbøll, T., & Knop, F. K. (2023). Dasiglucagon Treatment for Postprandial Hypoglycemia After Gastric Bypass: A Randomized, Double-Blind, Placebo-Controlled Trial. Diabetes Care, 46(12), 2208-2217. https://doi.org/10.2337/dc23-1193

Vancouver

Nielsen CK, Øhrstrøm CC, Houji IJK, Helsted MM, Krogh LSL, Johansen NJ, et al. Dasiglucagon Treatment for Postprandial Hypoglycemia After Gastric Bypass: A Randomized, Double-Blind, Placebo-Controlled Trial. Diabetes Care. 2023;46(12):2208-2217. doi:10.2337/dc23-1193

BibTeX
@article{Nielsen2023,
  author = {Nielsen, Casper K and Øhrstrøm, Caroline C and Houji, Inas J K and Helsted, Mads M and Krogh, Liva S L and Johansen, Nicklas J and Hartmann, Bolette and Holst, Jens J and Vilsbøll, Tina and Knop, Filip K},
  title = {Dasiglucagon Treatment for Postprandial Hypoglycemia After Gastric Bypass: A Randomized, Double-Blind, Placebo-Controlled Trial},
  journal = {Diabetes Care},
  year = {2023},
  volume = {46},
  number = {12},
  pages = {2208--2217},
  doi = {10.2337/dc23-1193}
}
Kostenlos starten →